Remote care may reduce heart failure events

• by Kerri Miller

• October 26, 2026

FDA updates PAH label with trial data

In adults diagnosed with pulmonary arterial hypertension within the previous year, adding sotatercept to background therapy reduced the risk of clinical worsening events by 76% compared with placebo.

• by Kathryn Wighton

• September 22, 2026

• 3 min

Influence of left ventricular ejection fraction on the clinical outcome of percutaneous coronary interventions in heart transplant patients

• by Luisa Elbinger, Tobias Schupp, Michael Behnes, Ibrahim Akin, Angelika Costard-Jäckle, Rene Schramm, Tanja Rudolph, Volker Rudolph, Mohamed Ayoub

• October 7, 2026

Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Across the Ejection Fraction Spectrum: A Multistate Real-World Cohort

• by MICHEL CHEDID EL HELOU, KARIM HOYEK, HARSH PATOLIA, MICHAEL HILL, ZIAD ZALAQUETT, HUNTER BLOCK-BEACH, ASHISH SARRAJU, AMANDA R. VEST, NANCY M. ALBERT, RANDALL C. STARLING, TREJEEVE MARTYN

• October 10, 2026